The Indonesian healthcare biotechnology startup PathGen Diagnostik Teknologi announced that East Ventures and Royal Group Indonesia, two venture capital firms, had contributed funds to the company.
According to a statement from PathGen, the cash will go into a number of important initiatives, including R&D, technological advancement, market expansion, and others.
“We are confident that this funding will propel us forward in our mission to improve lives by democratizing molecular testing solutions that suit the local context,” said Dr. Susanti, Co-Founder and Chief Executive Officer of PathGen.
Although not everyone has the resources to do so, the founders feel that early disease detection and access to more targeted therapy are essential for preventing health issues.
With the goal of democratizing genomics solutions in lower- and middle-income nations, PathGen is a company that offers affordable molecular diagnostic tools for cancer and other disorders in Indonesia.
Read also – India-Based Avaada Energy Secured $535 Million in Refinancing
For assessing prognosis, forecasting treatment outcomes, and identifying familial risks, PathGen offers easily accessible and trustworthy molecular diagnostics solutions. The company is presently creating a variety of molecular genetic testing kits for lung, colorectal, cervical, and nasopharyngeal cancers.
These kits are mostly polymerase chain reaction-based in order to simplify testing and improve uptake in the Indonesian market. Through the creation of cutting-edge technologies like Next-generation sequencing for cancer and other disorders, PathGen is also advancing molecular diagnostics. NGS has completely changed the field of genomics by making it possible to quickly and affordably analyze big genomes and to profile diseases in-depth.
Read also – India-Based Ecozen Secured $30 Million in Debt-Equity Funding
By maximizing drug selection and dose for specific patients, this method supports customized medicine by identifying genetic variations connected to drug response and metabolism.
About PathGen
PathGen Diagnostik Teknologi was founded by Susanti with the intention of developing a portfolio of training and research projects in conjunction with Indonesian peers. The creation of reliable, affordable molecular diagnostic tools and the development of capacity to efficiently apply these technologies are the company’s main priorities.
